In light of RCTs, associated meta-analysis and systemic reviews, SGLT2 inhibitors are now commonly recommended for the treatment of most patients with DKD and an eGFR of ≥25 mL/min per 1.73 m2, irrespective of the glycemic management status [138,139]. Here, SLC5A2 is linked to diabetic kidney disease.